Assessing Platelet Inhibitory Response to Clopidogrel – Feasibility, Safety and Cost Analysis of a Tailored Platelet Inhibition Strategy for Elective PCI Patients - Plavix and Prasugrel
- Conditions
- To investigate the feasibility, safety and cost of using the platelet assay VerifyNow-P2Y12 to guide optimal P2Y12 platelet inhibition in patients undergoing elective PCI, compared with standard treatment, at a UK tertiary referral cardiology centre.
- Registration Number
- EUCTR2010-018435-18-GB
- Lead Sponsor
- Papworth Hospital NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Age >18
Able to consent
Elective PCI
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Contraindication to clopidogrel, aspirin or prasugrel
Weight <60kg
Previous stroke / TIA
Age > 75
Pregnancy
Breast-feeding women
Warfarin
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method